Published in final edited form as:

N Engl J Med. 2016 December 29; 375(26): 2596–2598. doi:10.1056/NEJMe1611723.

Breathing Easier with Fish Oil — A New Approach to Preventing Asthma?

Christopher E. Ramsden, M.D.

Lipid Mediators, Inflammation, and Pain Unit, Laboratory of Clinical Investigation, National Institute on Aging, in Baltimore, and the National Institute on Alcohol Abuse and Alcoholism, in Bethesda, MD

Asthma and lower respiratory infections are leading causes of morbidity and mortality in pediatric populations. Thus, having low-cost, effective, safe options for prevention could have important implications for both clinical practice and public health.

In this issue of the *Journal*, Bisgaard and et al.¹ report that high-dose supplementation of the n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) derived from fish oil in the third trimester of pregnancy significantly decreased the risk of persistent wheeze and asthma (the primary outcome) during the first 5 years of a child's life. The intervention also decreased the rate of lower respiratory infections (a secondary outcome) but had no significant effect on allergic rhinitis or eczema. No major side effects were reported. Major strengths of the trial include its double-blind, randomized, placebo-controlled design, moderate-to-large sample size, low dropout rate, and extensive use of clinical phenotyping.

A particularly salient finding was that the preventive effect of fish oil was driven almost exclusively by children of the prespecified subgroup of mothers with low baseline blood levels of EPA and DHA (relative reduction in risk of persistent wheeze and asthma, 54%; $P = 0.011$). Effects were most evident in children of mothers with a variant of the gene encoding fatty acid desaturase that is associated with low ability to produce EPA and DHA from their dietary precursor, alpha-linolenic acid. Together, these observations support the plausibility of the findings and point toward a precision-medicine approach in which factors such as blood levels of fatty acids, genotype, and parental history of asthma could potentially be used to tailor interventions to those most likely to benefit. These results also highlight the importance of measuring baseline EPA and DHA levels in future trials involving fish oil.

The findings of Bisgaard et al. build off an extensive body of preclinical work linking lipid mediators to inflammation and could provide clues to the fundamental mechanisms underlying the development of asthma. It is well known that the EPA and DHA present in foods and fish oil increase blood levels of EPA and DHA and displace arachidonic acid in membrane phospholipids that serve as precursors for the biosynthesis of lipid mediators.² Leukotrienes made from arachidonic acid³ — including leukotrienes B₄, C₄ and D₄ — are

potent mediators of bronchoconstriction and airway inflammation⁴; this knowledge spurred the development of antileukotriene medications, whose use is well established in the treatment of asthma in adults.⁵ In preclinical studies, lipid mediators derived from EPA and DHA dampen airway hyperresponsiveness,^{6,7} promote the resolution of inflammation,⁸ and protect against viral infection.⁹ When these observations are taken together, it is tempting to speculate that the preventive effects of fish oil on asthma and respiratory infections are due to shifts in the balance of lipid mediators away from inflammation and bronchoconstriction and toward the resolution of inflammation and host defense (Fig. 1).

Although these results are highly promising, a note of caution is warranted. The dose of EPA plus DHA provided in this trial (2.4 g per day) was approximately 15 to 20 times as high as the average U.S. intake from foods. Before these findings can be applied to clinical practice, it is therefore imperative to ensure that this dose had no adverse effects on behavior, cognition, or other long-term outcomes. Future work is also needed to determine whether lower doses are effective and whether these results can be replicated in other populations.

References

1. Bisgaard H, Stokholm J, Chawes BL, et al. Fish oil–derived fatty acids in pregnancy and wheeze and asthma in offspring. *N Engl J Med*. 2016; 375:2530–9. [PubMed: 28029926]
2. Lands WE, Libelt B, Morris A, et al. Maintenance of lower proportions of (n–6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n–3) fatty acids. *Biochim Biophys Acta*. 1992; 1180:147–62. [PubMed: 1463766]
3. Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. *J Clin Invest*. 1984; 74:1922–33. [PubMed: 6096400]
4. Weiss JW, Drazen JM, McFadden ER Jr, et al. Airway constriction in normal humans produced by inhalation of leukotriene D: potency, time course, and effect of aspirin therapy. *JAMA*. 1983; 249:2814–7. [PubMed: 6842792]
5. Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. *Proc Assoc Am Physicians*. 1999; 111:547–59. [PubMed: 10591083]
6. Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. *J Immunol*. 2007; 178:496–502. [PubMed: 17182589]
7. Flesher RP, Herbert C, Kumar RK. Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma. *Clin Sci (Lond)*. 2014; 126:805–14. [PubMed: 24344649]
8. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature*. 2014; 510:92–101. [PubMed: 24899309]
9. Morita M, Kuba K, Ichikawa A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. *Cell*. 2013; 153:112–25. [PubMed: 23477864]

Figure 1. Model Depicting Fish Oil-Induced Alterations in Lipid Mediators of Inflammation and Bronchoconstriction

Leukotrienes synthesized from arachidonic acid mediate bronchoconstriction and airway inflammation (Panel A). The docosahexaenoic acid and eicosapentaenoic acid in fish oil displace arachidonic acid in membrane phospholipids, which serve as precursors for biosynthesis of lipid mediators. This effect shifts the balance away from mediators of inflammation and bronchoconstriction and toward the resolution of inflammation and host defense (Panel B).